Active mechanisms of ketamine-assisted psychotherapy: A systematic review.
Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo, Felicia Ceban, Shakila Meshkat, Leanna M.W. Lui, Farhan Fancy, Joshua D. Rosenblat, Roger S McIntyre
Journal of Affective Disorders October 15, 2022 DOI: 10.1016/j.jad.2022.07.030 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant depression or substance use disorders |
| Intervention | Ketamine-assisted psychotherapy |
| Topics | Ketamine Esketamine Psychedelic-assisted therapy |
| Keywords | Mood disorders Psychedelics Psychotherapy Rapid acting antidepressants Substance-use |
| Key findings | Ketamine-assisted psychotherapy had a significant positive effect on primary outcome measures compared to controls, but the data is mixed and the single trial for treatment-resistant depression found no benefit. |
Abstract
Few studies have evaluated the efficacy of ketamine-assisted psychotherapy (KAP) in the treatment of treatment-resistant depression (TRD) and substance use disorders (SUD). A systematic review of clinical trials reporting on the efficacy of KAP and discussing mechanisms of action, identified on PubMed and PsycInfo. Five randomized-controlled trials reported on the efficacy of KAP treatment and discussed active mechanisms. Four of the studies treated adults with SUD and a single study treated adults with TRD. Overall, KAP had a significant positive effect on primary outcome measures compared to controls, however, the data is mixed. The study examining KAP for TRD found no benefit. Lack of large, replicated clinical trials. No studies actively examining mechanisms of action. Evidence suggests that temporary neural changes caused by ketamine such as n-methyl-d-aspartate receptor (NMDAR) inhibition and increase of synaptic neuroplasticity affect treatment outcomes of KAP. Based on reports of preliminary findings, we speculate that adjunct psychotherapy, changes in perspective, and spirituality may also play a role.
Comparable studies
Other systematic reviews and meta-analyses on ketamine and psychedelic-assisted therapy, most cited first.
Citations in the library
Cited by 45
- Randomized trial of ketamine masked by surgical anesthesia in patients with depression Nature Mental Health October 19, 2023
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment Current Neuropharmacology January 5, 2024
- Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology July 24, 2023
- Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review BJPsych Open May 1, 2023
- The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression Frontiers in Psychiatry September 19, 2023
and 40 more in the library
Cites 20
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- Global Street Food: la cocina de la calle Diseño interior 2009
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) Molecular Psychiatry October 3, 2018
- A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide. Psychopharmacology Bulletin March 4, 2024
- Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Journal of Psychoactive Drugs June 1, 1997
and 15 more in the library